Symposia

INDUSTRY SUPPORTED SATELLITE SYMPOSIA

Sunday, 22 September 2019
EICC, Pentland, Level 3
07:00 – 08:00

Leveraging Next-Generation BTK Inhibitors in B-Cell Malignancies: Data Updates and Case Challenge

Supported by an independent education grant from Acerta Pharma – A member of the AstraZeneca Group.

Program Overview

Patients with B-cell malignancies, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), require individualized treatment. In recent years Bruton tyrosine kinase (BTK) inhibitors have become available and have dramatically changed the treatment landscape for patients with B-cell malignancies. The availability of BTK inhibitors has had a particularly significant impact on the treatment of CLL, especially in the treatment-naive setting. Several novel BTK inhibitors are in development for the treatment of CLL and other B-cell malignancies.

This interactive, case-based satellite symposium is designed to improve the knowledge of hematologists/oncologists about the latest data on use of BTK inhibitors for the treatment of B-cell malignancies. Come hear experts discuss the evolving CLL treatment paradigm and the current role for BTK inhibitors in MCL and CLL. A focus of the symposium will be an interactive case where the audience will interact with the experts through iPad polling questions and will receive real-time feedback about answer choices.

Program faculty
Moderator

Jacqueline C. Barrientos, MD, MS
Associate Professor
Zucker School of Medicine at Hofstra Northwell
New Hyde Park, New York, United States

Panelist

Barbara Eichhorst, MD
Associate Professor
Consultant Hematologist
Department of Internal Medicine
Secretary of the GLLSG
University Hospital of Cologne
Cologne, Germany

Paolo Ghia, MD, PhD
Associate Professor
Director, Strategic Research Program on CLL
Università Vita-Salute
San Raffaele
Milano, Italy

Medscape, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Register Here

 

Program Agenda
7:00
Welcome and Introductions
Jacqueline Barrientos, MD, MS
7:05 The Current Role of BTK Inhibitors in MCL and CLL
Paolo Ghia, MD, PhD
7:20 The Evolving CLL Treatment Paradigm
Barbara Eichhorst, MD
7:40 Future Directions
Paolo Ghia, MD, PhD
7:45 Summary and Conclusions
Jacqueline Barrientos, MD, MS
7:50 Panel Questions and Answers
All Faculty

Sunday, 22 September 2019
EICC, Pentland, Level 3
14:00 – 15:25

Selecting the Right Strategy for the Management of Patients with Treatment-Naïve CLL

An iwCLL symposium supported by Janssen Oncology

Program Overview

After participating in this symposium delegates should be able to discuss the management of treatment-naïve patients with CLL.

Scientific chair

Peter Hillmen, MB ChB, PhD
The Leeds Teaching Hospitals, St. James’s University
United Kingdom

Program Faculty

Paolo Ghia, MD, PhD
Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele
Milan, Lombardy
Italy
Peter Hillmen, MB ChB, PhD
The Leeds Teaching Hospitals, St. James’s University
United Kingdom

Tait Shanafelt, MD
Stanford University, School of Medicine
Sanford, California
United States

William Wierda, MD
University of Texas MD Anderson
Houston, Texas
United States

Program Agenda
14:00
Introduction
Peter Hillmen
14:05 The Evolving Standard of Care for Treatment-Naïve Patients With CLL
Tait Shanafelt
14:25 Future Chemotherapy-Free Combinations
William Wierda
14:45 Integration of Biomarkers into Treatment Decision-Making – More Important Than Ever?
Paolo Ghia
15:05 Roundtable Discussion Panel Discussion with Interactivity and Audience Q&A

Monday, 23 September 2019
EICC, Pentland, Level 3
7:00 – 8:00

Treatment of CLL and the Value of Testing for Minimal Residual Disease (MRD)

An industry satellite symposium supported by Adaptive Biotechnologies

Program Overview

Accurate quantitation of post-treatment residual disease burden in chronic lymphocytic leukemia (CLL) is prognostically relevant. Minimal residual disease (MRD) status has been shown to be a predictor of both progression-free survival (PFS) and overall survival (OS) at the time of response assessment. The goal of this activity is to improve knowledge of clinical trial data and best practices on the use of minimal residual disease (MRD) measurement in the management of patients with CLL.

Program Faculty

Anna Schuh, MD, PhD
Director of Molecular Diagnostics
Oxford NHS/BRC Molecular Diagnostics Centre
University of Oxford
Oxford, UK

Javier Pinilla-Ibarz, MD, PhD
Director of Immunotherapy, Malignant Hematology Division
H. Lee Moffitt Cancer Center & Research Institute
Assistant Professor, Department of Oncologic Sciences
University of South Florida
Tampa, FL

Register Here

 

Program Agenda
7:00
Welcome and Introduction
Anna Schuh, MD, PhD
7:00 What is MRD and Why is it Important?
Anna Schuh, MD, PhD
07:05 How is MRD Measured?
Anna Schuh, MD, PhD
07:15 Clinical Data with MRD Testing
Anna Schuh, MD, PhD
07:25 Integrating MRD Testing Into Clinical Practice
Javier Pinilla-Ibarz, MD, PhD
07:40 The Future of MRD Analysis in CLL
Javier Pinilla-Ibarz, MD, PhD
07:50 Q&A